PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95957

Guangxia GAO, et al.

Appln. No.: 10/585,863

Group Art Unit: 1645

Confirmation No.: 7734

Examiner: Not Yet Assigned

Filed: July 11, 2006

For:

THE RECOMBINANT MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASES,

THE GENES ENCODING AND THE METHOD FOR EXPRESSING IT

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

MAIL STOP SEQUENCE Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In connection with the substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- 1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include any new matter;
- 2. the contents of the 8-page substitute Sequence Listing being filed herewith, and the attached computer readable copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
- 3. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by

STATEMENT TO SUPPORT FILING

U.S. Application No.: 10/585,863

Attorney Docket No.: Q95957

fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Applicants respectfully request amendment of the application by entry of the substitute Sequence Listing into the application in place of the Sequence Listing filed with the application.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

CUSTOMER NUMBER

Date: September 11, 2007